The presence of tum or-infilt rating lymphocytes has been show n to significantly imp rove clin ical outcomes in many types of cance l: However; their effe cts on outcomes in patie nts with orophary nge al cance r specifically have ye t to be elucidated. We con ducted a retrospective study in an effo rt to shed light on this issue . We review ed the records of48 consec utively presenting pa tients with oropharyngea l cancel;and weperform edimmunohistochemist ry to analyze their archived paraffin-embedd ed tissue samples fo r the presence ofCD3-positive tum or-infilt ratin g lymphocytes. We also used real-time po lyme rase chain reaction testing to look fo r hum an p apilloma virus type 16 in the tum ors. We fo und that patients with large numbers of tum or-infiltratin g lymph ocytes (CD3 high ) had a significantly lower incidence of metastas is at presentation than did those with low numbers oftumor-infi ltrating lymphocytes (CD3'o,,') (40.0 vs. 88.5%; p =0.001), regardless of HP V status. When HPV status was taken into account, the correlati on between a high CD3 count and a lower rate of metastasis was ma inta ined in the HPV-p ositive patients but not in the HPV-negati ve patients. We also fo und that the CD3 high patients had higher rates of overa ll surviv al and disease -f ree survival at 3 and 5 years than did the CD3'oW patients; however, these differences only approached but did not reach statisti cal significance.
Introduction
Human papilloma virus (HPV) -associated head and neck squamous cell carci noma (HNSCC) is a uniqu e form of cancer. Between 15 and 23% of all HNSCCs are assoc i-ated with HPV infecti on; as many as 115,000 cases are diagnosed each year globally.' ? The most common site of HPV-associated HNSCC is the oropha rynx, and the type of HPV most often identified in HPV-associated HNSCC is HPV type 16. s . 6 The management of this distinct type of HNSCC presents otolaryngologists with new challenges and new opportunities. The presence of viral proteins within tumor cells pro vides well-characte rized targets for novel diagnostic, preventive, and therapeutic modalities. One such novel therapeuti c modality is immunotherapy. The goal of immunotherap y is to generate an immun e response capable of eliminating bulky tum ors. Several therapeuti c head and neck cancer vaccines are being investigated in preclinical and/or clinical trials. I .? The se vaccines are designed to create a tumor-infiltrating lymphocyte response that will lead to the elimination of cancerous cells.
Studies have shown that the number of tumor-infiltrating lymph ocytes in a tumor is correlated with survival in several different types of cancer, includin g ovarian,' pancreatic," skin,"and oral'? cancer. Howe ver, to the best of our knowledge , no similar study of tumo r-infiltrating lymph ocytes in oropharyngeal cancer has been published.
In this article, we describe our investigation into whether the number of CD3-positive tumor-infiltrating lympho cytes is correlated with clinical outcome in a cohort of patients with oropharyngeal ca ncer in general and HPV-associated HNSCC in particular.
Patients and methods
We reviewed the case records of 48 consecutively presenting patients--40 men and 8 women , aged 37 to 83 years (mea n: 58.8)-who had been treated surgically for squamous cell carci noma of the oropharynx at the Hospital of the Univers ity of Pennsylvania from Januar y 1996 throu gh December 200 I. In addition to demographic data, we recorded data on tumor site and tumor stage at presentati on. Tumors were staged in accordance with American Joint Committee on Cancer criteria.
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We also noted the length of overa ll survival and diseasefree survival during follow-u p (mea n 38.6 mo) and the incidence of metastasis at presen tation:
• Overall survival was calculated from the date of treatment to either the date of death or the date of the last documented clinical encounter.
•A recurren ce was defined as the presence of a pathologically verified squamous cell carcinoma in the oropharynx after initial surgical treatment. Disease-free survival was calcul ated from the date of treatment to the date when a recurrent squamous cell carcin oma was documented at the primary site or in the neck .
• The presence or absence of regional lymph atic metastasis at presentation was determined ( I) by histologic confirmation of a positive neck node in those cases in which a neck dissection was performed or (2) by clinical and/or radiographic analysis in the abse nce of a neck dissection. Patients were deemed to be NOif findings on neck dissection were negative or if preoperative computed tomography (CT) demonstrated no pathologica lly enlarged nodes.
DNA extractionfrom paraffin sections. Tissue samples were obtained in accor dance with a protocol approve d by the Institutional Review Board of the University of Pennsylvania.
Paraffin-embedded tissue was taken from each of the tumor samples in 7-to IO-mm sections, and the sectio ns were mounted on glass slides. On the slides, areas of squamous cell carcinoma were outlined on a hematoxylin-and eosin-stained slide by a board-certified patholog ist (E.E.). DNA was extracted by scraping each slide with an I8-g auge needl e in the area that the pathologist had labeled T UM OR. The QIAamp DNA Mini Kit (Qiagen; Valencia, Cal if.) was used to purify the DNA.
Briefly, the protocol was carried out thus:
The samples were deparaffinized with xylene. The cells then were resuspended in Buffer ATL and digested with the Proteinase K solution provided in the kit. The samples were then incub ated at 56°C for 3 hours on a rocking platform to ensure inactivation of the Proteinase K. Protein was precipitated with Buffer AL and incubated at 70°C for 10 minut es. Ethanol (100%) was then added to the sample to precipitate the DNA. The mixture was applied to a QIAamp spin column in a 2-ml collection tube and centrifuged at 20,000 x g (14,000 rpm) for I minut e. The filtrate was discarded, 500 J..IL of Buffer AW l was added to the column in a clean 2-ml collection tube, and the tube was centrifuged at 20,000 x g for I minute. Next, the filtrate was discarded, 500 J..IL of Buffer AW2 was added to the column in a clean 2-ml collection tube, and the tube was centrifuged at 20,000 x g for 3 minute s. Finally, the Vo lum e 86, Num ber 8 sample was rehydrated with Buffer AE. All samples were stored at 4°C for later use.
Polymera se chain reaction. The integrity of the DNA was verified by conventional polymerase chain reaction (PCR) assay with 2 sets of primers. Sampl es were amplified with primers (PC04/GH20) specific for the humang lobin gene. The amplicon size was 268 base pairs.
The forward primer sequence was: GH20 (GGG GAA GAG CCA AGG ACA GGT AC) .
The reverse primer sequence was: PC04 (GGG CAA CTT CAT CCA CGT TCA CC) .
Samples were also amplified with primers specific forthe BRAF gene, which encodes a ubiquit ous serine/threonine kinase. The amplicon size was 280 base pairs.
The forwar d primer sequence was: 5'-GGC CAA AAA TIT AAT CAG TGG A-3'.
The reverse primer sequence was : 5'-TCA TAA TGC TTG CTC TGA TAG GA-3' .
Only those DNA samples that were of sufficient quality to be amplified by both sets of primers were included in this study.
Quantitative real-time peR for HPV-16 detection.
Quantitative PCR was performed with an ABI Prism 7900HT Sequence Detection System (Applied Biosystems; Foster City, Calif.).
The forward primer sequence was: E7 5'-GGA TGAAAT AGA TGG TCC AGC TG-3 ' .
The reverse primer sequence was: E7 5'-CAC TTG CAA CAA AAG GTT ACA ATA TTG -3' .
The probe sequence was: E7 5' -FAM-ACA AGC AGA ACC GGA CAG AGC CCA TT-TAMRA-3' .
The E7 primers and probe were used to amplify HPV-I6 E7 from lOng of each sample DNA in triplicate. We also used DNA from the CaSki cell line (600 viral copies of HPV-16/cell) in our analysis. In order to standardize the DNA, we raneach of these samples with the~globin primers and probe (Applied Biosystems) simultaneously with the E7 primers. Using serial diluti ons of CaSki DNA (50 ng, 5 ng, 0.5 ng, 0.05 ng, and 0.005 ng), standard curves were developed for HPV copy number as well as for~globin. The HPV copy number is determined by comparing the data generated by our unknown samples with that of the CaSki DNA. An HPV copy number greater than O.l/cell was considered positive for HPV- 16 .
Tissue microarray construction. The microarray was made at the Pathology Core of the Childr en's Hospital of Philadelphia. In brief, 0.6-mm core samples were taken from the paraffin-embedded tumor tissues and assembled on a recipient paraffin block with a micrometer-precise coordinate system for assembling tissue cores on a block. Six cores from each tissue sample were placed at l -mm intervals on the block. After construction, multiple 5-l-lm sections were prepared with a microtome for immunohistochemical analysis.
Immunohistochemical staining. The paraffin-embed- ded slides were then stained for the expression of CD3 in the Pathology Core at the Hospital of the Univers ity of Pennsylvania. (CD3 is a complex of four transmemb rane signa ling chains that is present on most lymphocytes. CD3 polyclonal rabbit antihuman antibody was provided by the Core.) The slides were deparaffinized and hydrated with xylene and a graded alcohol series. Slides were then heated with l x citrate buffer (10 mM; pH : 6.0; Lab Vision; Fremont , Calif.) for 8 minutes in a 1,200-W oven at 70% power. Slides were then cooled for 20 minute s. Primary antibody was applied to the slides for 30 minute s. The slides were washed and incub ated with biotinylated goat secondary IgG for 30 minute s at room temperature. Then the slides were washed again and processed with the horseradish peroxidase-based EnVision System (Dako-Cytomation; Carpinteria, Calif.). The slides were washed again, counterstained with hematoxylin, and dehydrated with a graded alcohol series. The slides were then exa mined by the pathologist, who determined the degree to which CD3-positive cells were present in the tumor (figure I). Samples were graded on a scale of 0 to 3+: 0 (no posi tively staining cells), 1+ (few), 2+ (a moderate amount), or 3+ (many). All the slides were read at one sitting in a blinded fashion.
Each of the cores corresponding to a patient 's tumor was graded individually, and the scores were averaged so that a representative score could be assigned to each tumor. Tumors were classified as either CD3 10w (mean score:~1) or CD3 high (> 1).
Statistical analysis. Prognostic covar iates included in the statistical analysis were the degree of CD3 infiltration, the stage of disease at presentati on, HPV status, and rates of overall survival, disease-free survival, and metastasis. Correlation between CD 3 infiltration and HPV status with the other prognostic variables was evaluated according to Fisher's exact test or the chi-square test for trend .Analysis of differences in overall survival between groups was based on the log-rank statistic and Kaplan-Meier analysis. (table I) . It is interesting that when data were analyzed according to T category, 10 of25 CD3 10w patients (40.0%) presented with a catego ry T4 lesion, compared with only 3 of the 22 CD3 high patients (13.6%) (figure 2). The difference approached statistical significance (p = 0.0561). (For I of the CD3 10w patients, sufficient data were not available to accurately assign aT category, althou gh we know that the patient did have stage IV disease because of doc ume nted cerv ical metastase s.) HP V-16 status. Amo ng the entire group of 48 patien ts, 33 patie nts (68 .8%) were HPV-positive. Of these 33, 17 (51.5 %) were CD3 high and 16 (48.5%) were CD3 1ow • Of the 15 HPV-negative patie nts, 5 (33.3%) were CD3 high and 10 (66.7%) were CD3 1ow • Survival. The CD3 high patients had a higher overall survi val rate than did the CD3 10w patient s at 3 years (77 vs. 64%)and at5 years (77% vs. 51%), butthedifferences were not statistically sign ificant (p = O. I52) ( figure 3, A) .
Disease-free survi val rates were also higher in the CD3 high patients at 3 years (7 1 vs. 44 %) and at 5 years (7 I vs. 37%). Th ese differences approac hed but did not reac h statistica l sig nificance (p = 0.09) ( figure 3, B) .
Metastasis. Of the 48 patie nts, 46 had undergone either a neck dissec tion or CT that objective ly doc umented the presence or absence of! ymphatic disease.Among these 46 patie nts, we found a strong corre lation between the degree of lymphocytic infiltration and the presence or absence of met astasis at presentation. Among the 20 CD3 high patients, only 8 (40.0%) had documented metastasis (table  2) . By cont rast, metastasis was documented in 23 of 26 CD3 10w patients (88.5%). The difference was statisticall y significant (p = 0.00 1).
Because metas tasi s was the most significant clinical parameter we found, we exte nded our analysis to exa mine its correlatio n with CD3 and HPV status. Of the 17 patient s who were CD3 high and HP V-positive, accurate lymphatic staging was avail able for 16. Of these 16, only 6 (37.5%) had metastatic disease at presentation, compared with 14 of 16 CD3 10w and HPV-po sitive patient s (87.5%) (table 3). Thi s difference was statistically significa nt (p = 0.009 ).
Ahigh CD3 count prov ided no such significa nt benefit in HPV-negative patient s.The CD3 high HPV-negat ive patients for whom accurate metastasis data were ava ilable had a much higher rate of metastasis (3 of 4 ; 75.0 %) than did the CD3 high HPV-po sitive patie nts (37.5 %). Among the CD3 10w patien ts, 9 of 10 HPV-negative patien ts (90.0%) had metastatic disease at presentation, a rate comparable to that among the HPV-positive pat ients (87.5%). The difference between rates of metastasis between CD3 high and CD3 10w HPV-negative patients was not statistically significant (p = 0.5055) (table 3) .
Finally, we compared rates of metastasis according to HPV status in CD3 high patients alone. We expec ted that the differe nce would not be statically sig nificant and, indeed, the p value was 0.6090 (data not show n). ... Statistical sign ificance p = 0.001* • Second, the presence of tumor-infilt rating lymphocyte s in the tumor may reflect the pre sence of tumo r-specific lymphocytes in the drainin g cervical lymph node s.Tumorspecific lymphocytes in the lymph node s may then target metastatic tum or cell s and eliminate them at a higher rate in CD3 high patients. Studies are under way to help confirm the pre sence of tumor-specific lymphocytes in the lymph node s in certain oropharyngeal cancer patient s. Table 3 . Inc idence of lymph node metastasis according to CD3 status and HPV status in patients wh o un derw ent neck dissection or preoperative CT (n =46)
Ai
• Fir st, it is conceivable that the presence of these lympho cytes helps to limit tumor volume and tumor invasiveness, which may prevent metastasis. We saw far more T4 lesion s in CD3 10w patients than in CD3 high patients.
Discussion
In this study, we showed that the presenc e oflarge numbers of tumor-infiltrating lymphocytes was inver sely correlated with the incidence of nodal metastasis in our cohort of patients with oropharyngeal squamous cell carc inoma , particularly those who were HPV-positive. Thi s finding illustrates the important role that the immune system may play in influencing the cour se of oropharyngeal cancer. The importance of the immune system in controlling other types of canc er is well documented. For example, immunocompromi sed patient s are known to be at high risk for different type s oflymphomas. " With regard to head and neck cancer , the evidence is more indi rect, but it is still convincing. It has been shown that many head and neck cancers probably evade immune surveillance by downregulat ing key immunologic molecules " and by creating a tumor microenvironment hostile to immune function. 10.13·15 Two reasons can be postul ated to explain the relation ship between tumor-infiltrating lymphocytes and metasta sis:
Metastasis n (%)

Statistical significance
Most of the oropharynge al cancer patients in our cohort were HPV-16-positi ve. It is well documented that HPVpositive patients tend to ha ve better clinical outcomes than do HPV-negative patients," and we attempted to determine whether tumor-infiltrating lymph ocyte s may play a role in that difference. Our finding that a large numb er of tumor-infiltrating lymphocytes was correlated with a lower rate of metasta sis in HPV-po sitive tumors but not in HPV-ne gative tumors must be examined in light of the fact that the size of our sample of HPV-negative patients was small. However, this trend begs an important que stion: Are the tumor-infiltrating lymph ocytes in HPV-positive tumors better able to limit tumor progression because of a stable tumor antigen, which is not present in HPVnegati ve tumors ? There is evidence that HPV-specifi c lymphocytes are present in the circulation of HPV-associated oropharyngeal cancer patients.t-" and studies are under way in our labo ratory to determine what pe rcentage of lymphocytes in the tumor are HPV-spe cific. If we can show that the presenc e of HPV-spe cific tumor-infiltrating lymphocytes correlate s with better clinical outcomes, we would provide further justification for efforts to dev elop immunotherapeutic strategies that generate these tumorinfiltrating lymphocytes.
In conclusion , our results show a correlation between a high degree of lymphocyte tumor infiltration and a low rate of metastasis in oropharyngeal cancer pati ent s. Thi s correlation was maintained in the subset of HPV-po sitive patients, but not in HPV-ne gative patients. This finding ha s direct implications on the future prognostic and immunotherapeutic mod alitie s forthis clinical entit y. Further investigation of the effect of HPV on tumor-infi ltratin g lymphocytes and the tumor microenvironment in general is warranted .
* Two-sided Fisher 's exact test.
HPV·positive (n =32) C D3 high (n = 16) C D3 1 0w (n = 16) HPV-negative (n =14) CD 3 high (n = 4) C D3 1 0w (n = 10) 6 (37.5) 14 (87.5) 3 (75.0) 9 (90 .0) p = 0.009* p = 0.5055*
